INTRODUCTION
Melanoma is the deadliest form of skin cancer accounting for only 4% of all skin cancer cases but for 80% of all skin cancer-related deaths. 1 Melanoma has become the most common form of cancer for young adults between 25 and 29 years old. 2 Because melanomas are highly resistant to the majority of standard therapies, the 5-year survival rate for patients with advanced disease is o15%, which underscore a clear need for novel more effective therapies. The identification of the signaling pathways that are altered in melanoma provides opportunities for the development of such treatments.
Recent evidence suggests that normally dormant embryonic stem cell pathways may be reactivated in melanoma and contribute to melanoma tumorigenicity. 3 The Notch pathway is an evolutionary conserved signaling cascade that has an essential role in embryonic development and cell renewal in the adult by participating in the maintenance of stem cell pluripotency in a variety of tissues. 4 --6 Remarkably, Notch signaling has been linked to the genesis and/or progression of tumors that originate in the same tissues. 7 --14 In the melanocytic lineage, elevated Notch1 signaling has a key role in melanoblast and melanocyte stem cell homeostasis. 15 While Notch1 expression is normally decreased in mature melanocytes, melanomas regain expression and activity of Notch1. 16, 17 Notch1 has been shown to be required for melanoma formation 16 and to be able to transform primary human melanocytes and to confer metastatic properties to primary melanoma cells when over-expressed. 17 --19 Together, these findings suggest that Notch1 is able to control multiple aspects of melanoma growth and progression. The mechanisms, however, are still not well understood.
Neuregulins and the ERBB receptor signaling cascade also have key roles during embryogenesis 20 and are emerging as new players in melanoblast and melanocyte homeostasis. Neuregulin1 (NRG1) promotes melanoblast proliferation and survival and delays melanoblast maturation into melanocytes. 21 In addition, ERBB3 has been found elevated in malignant melanoma and associated with reduced patient survival, 22 whereas activating mutations in ERBB4 have been observed in 20% of melanomas. 23 The question of whether NRG1 signaling has a role in melanoma growth and progression remains unanswered. Furthermore, although both Notch1 and NRG1 signaling are involved in melanocyte lineage homeostasis, it is not known whether crosstalk between these two pathways exists and whether it is a factor in melanoma development. Such cross-talk, for example, is observed in Schwann cell precursors where Notch1 promotes Schwann cell generation in vivo by maintaining high levels of ERBB2; 24, 25 and in normal and cancer stem cells of the breast where ERBB2 and Notch1 control their reciprocal levels of expression leading to an enrichment in HER2/Notch expressing stem cells. 25, 26 Such enrichment in the cancer stem cell population results in increased migration, invasion and in vivo tumorigenesis.
In this study we show that Notch1 and NRG1 expression is associated in melanoma and that NRG1 is a previously unidentified, direct transcriptional target of Notch1. Furthermore, we show that NRG1 strongly affects melanoma growth both in vitro and in vivo through the modulation of the PI3Kinase/Akt signaling pathway and of the cell-cycle regulator p27 Kip1 . Taken together, these findings provide compelling evidence of the existence of a Notch1 --NRG1 autocrine signaling loop regulating melanoma growth.
RESULTS
Notch1 and NRG1 are associated in melanoma Given the fact that both Notch1 and NRG1 have been found to have a role in melanocyte precursor cell homeostasis, we wanted to determine whether a correlation between Notch1 and NRG1 signaling in melanoma existed. We analyzed a series of publicly available datasets in the Oncomine database, 27 two obtained from human melanoma tissue specimens 28, 29 and two from melanoma cell lines. 30, 31 In the Talantov dataset, we observed a significant correlation between NRG1 and Notch1 (R ¼ 0.445, P ¼ 0.0003) ( Figure 1a ) and between ERBB3, the receptor for NRG1, and HEY1, a direct transcriptional target of Notch1 (R ¼ 0.488, P ¼ 0.0002) (Figure 1b ). In the Riker dataset (Figure 1c) , a significant correlation between ERBB3 and Notch1 was found (R ¼ 0.328, P ¼ 0.0142). Finally, NRG1 and Notch1 expression correlated significantly in the cell line datasets as well (Figures 1d and e ; R ¼ 0.3, P ¼ 0.02 and R ¼ 0.35, P ¼ 0.018, respectively). As a confirmation of the data obtained from the correlation analysis, we assessed the expression levels of Notch1 and NRG1 signaling elements in nine human samples obtained from resected melanoma metastases. Seven out of nine samples (77%) concurrently expressed NRG1, ERBB3 and Notch1 at various levels ( Figure 1f) . Similarly, analysis of a number of human melanoma cell lines revealed that 10 out of 13 cell lines (77%) expressed high levels of NRG1 as compared with control melanocytes (Figure 1g ) and that 12 out of 13 cell lines were also expressing high amounts of ERBB3 and Notch1 when compared with melanocytes. Interestingly, the pattern of expression of active Notch1 (NIC in Figure 1g ) more closely correlated with the expression pattern of NRG1 in the cells analyzed. Together, these data support the existence of a correlation between Notch1 and NRG1 signaling. Furthermore, the fact that control melanocytes (M) showed no or low level of expression of either protein suggests that the NRG1 and Notch1 pathways may be reactivated as a result of malignant transformation.
Notch1 affects NRG1 expression through binding to the NRG1 promoter The findings presented above suggest that Notch1 and NRG1 may be co-activated. We next sought to determine whether a molecular link between the two proteins existed in melanoma. By using a melanoma cell line with elevated NRG1 and Notch1 expression (WM266-4, cell line # 12, Figure 1g , upper panel), we inhibited Notch1 by using two specific shRNA sequences against human Notch1. The knockdown was determined by quantitative Figure 1g ). NRG1 protein was also reduced following inhibition of Notch1 expression by the shN1-2 ( Figure 2b ). Vice versa, expression of the active intracellular domain of Notch1 (NIC) in cells with low or no Notch1 (V2387, cell line # 4), resulted in increased NRG1 transcript and protein (Figures 2c and d) . Together, these data suggest that NRG1 is a transcriptional target of Notch1.
Active Notch proteins act as transcriptional co-activators by participating in the transcription of genes in a complex with the DNA-binding protein CSL (CBF1, Su(H), Lag1). To determine if NRG1 is a direct Notch target, we searched for cis elements within the NRG1 promoter that might be occupied by Notch1. Three putative CSL/Notch-binding sequences (TGGGAA 33 ) were identified within a 5-kb sequence upstream the NRG1 transcription start site on either the sense or antisense DNA strand: one at À3805, one at À1700 and one at À403 (Figure 3a shows the sequences at À3805 and À403). The sites were then tested for Notch1 occupancy in K457 cells with a chromatin immunoprecipitation (ChIP) assay. To this end, K457 cells were infected with either shScramble (control) or shNotch1-2, fixed with formaldehyde and lysed for analysis of Notch1 --DNA complexes. Effective Notch1 knockdown was assessed by western blotting and showed a significant inhibition of the protein (Figure 3b ). PCR amplification of Notch1-associated DNA demonstrated enrichment of the À3805 site in the K457 shScramble cells compared with the K457 shNotch1 cells. In contrast, amplification of the À403 sites was unchanged by the level of Notch1 expression (Figure 3c ). Of the three CSL/Notch-binding elements, only the À3805 complexes with Notch1 as shown in Supplementary Figure 2 . Binding of Notch1 to the HES1 promoter was used as positive control and showed similar results to the ChIP performed on the NRG1 promoter ( Figure 3d ).
To conclusively confirm that Notch1 binds and transcribes NRG1, we created a series of reporter constructs encompassing a minimal promoter region of NRG1 (À777 to þ 193) and a sequence comprising the À3805 binding site (À3984 to À3644) in which the À3805 site was either left unchanged or mutated in the core region to prevent the binding of CBF1 (Figure 3e ). The reporter assay showed that transfection of an active Notch1-NIC construct into WM266-4 cells, resulted in a 13-fold induction of luciferase activity when compared with uninduced (pLM only) control (Figure 3f ), while the mutation in the À3805 site significantly reduced the reporter activity (Po0.05, Student's t-test). A reporter construct containing the HES1 promoter was used as positive control to assess the efficiency of the Notch1-NIC construct. Together, these data underscore a direct role for Notch1 in the modulation of NRG1 expression.
NRG1 signaling is required for melanoma cell growth The data presented thus far support a direct effect of Notch1 on NRG1 activation in melanoma. To test whether NRG1 has a role in melanoma, NRG1 was inhibited in melanoma cells and in vitro growth assessed. To control for off-target effects, two distinct shRNA sequences against NRG1 were employed. As shown in Figure 4a , the shRNAs inhibited NRG1 mRNA accumulation by 75 and 90%, respectively, and resulted in a correlated decrease in NRG1 protein (Figure 4c The NRG1 signaling pathway has been shown to trigger the activation of major survival and growth signaling cascades such as the PI3kinase and MAPKinase pathways.
32 --34 Interestingly, we found that knockdown of NRG1 affected the level of phosphorylation of Akt while leaving the MAPkinase signaling cascade, measured as phosphorylation of ERK1/2, unchanged ( Figure 4c ). Akt triggers a signaling network that positively regulates cell-cycle progression by increasing cyclin D1, by inhibiting p21 cip135 and by reducing p27
Kip1 levels. 36 --39 Although the knockdown of NRG1 by both shRNA sequences did not alter p21
Cip1 or cyclin D1 expression, it resulted in a significant accumulation of p27 Kip1 that was inversely correlated with the levels of inhibition of NRG1 ( Figure 4d ).
Since NRG1 is known to exert its activity through binding to the ERBB3 and ERBB4 tyrosine kinase receptors, 40 we next asked whether blocking receptor signaling might result in cell growth inhibition as is the case in cells ablated of NRG1. Indeed, we observed slower growth when cells were treated with an anti-ERBB3 antibody that competes for NRG1 binding with the endogenous receptor 41 ( Figure 5a ). Interestingly, as was the case following NRG1 knockdown, the inhibition of receptor activity resulted in the inhibition of PI3kinase/Akt signaling and in an increase in p27
Kip1 protein ( Figure 5b ). These data suggest that NRG1 promotes melanoma cell growth in part through the engagement of the ERBB3 receptor and the activation of the PI3Kinase/Akt signaling cascade.
NRG1 supports the tumorigenic potential of melanoma cells To assess the role of NRG1 as a promoter of the tumorigenic potential of melanoma cells, WM266-4 cells expressing shRNAs against NRG1 were either seeded in soft agar or implanted in vivo in immunodeficient mice. Efficient NRG1 knockdown was assessed by qRT --PCR and again showed a significant inhibition of NRG1 (Figure 6c ). The growth delay observed was more pronounced in tumors expressing the shNRG1-5, which is more effective at inhibiting NRG1 expression. In a similar manner, the growth of K457 cells in vivo was inhibited by the knockdown of NRG1 (Supplementary Figure 3f) . In addition, the tumor growth delay was associated with an accumulation of p27 Kip1 within the tumors to a degree that correlates with NRG1 inhibition: shNRG1-5 shows the highest p27
Kip1 accumulation in both the cytoplasm and the nucleus (Figure 6d ). This observation is in line with other findings where p27
Kip1 accumulation results in even distribution or the protein between the cytosol and the nucleus. 36 ,37 Notch1 levels were not affected by the NRG1 knockdown as shown by immunohistochemical staining using an anti-Notch1 antibody that recognizes the transmembrane form of Notch1 (Notch1-TM) (Figure 6d, lower panel) . Overall, we conclude that the NRG1 signaling pathway has a critical role in the growth and tumorigenic potential of melanoma cells.
NRG1 is required for Notch1-mediated melanoma cell growth Previous work by us and others have shown that Notch1 is required for the efficient growth of a number of cancer cells including melanoma, 16 breast 42 and leukemia. 43 Based on the data presented above, we hypothesized that Notch1 may modulate melanoma cell growth in part by regulating NRG1 expression. To test this hypothesis, cells expressing a control shRNA (shGFP) or a specific shNotch1 (shN1-2) were subjected to treatment with recombinant NRG1 for 4 days and the relative growth between control and treated groups was subsequently analyzed. While Notch1 knockdown resulted in a 70% growth inhibition compared with control cells, treatment with recombinant NRG1 led to a significant rescue of the growth capacity of cells depleted of Notch1 (Figure 7a ). Interestingly, Notch1 inhibition resulted in the inhibition of Akt phosphorylation that was reconstituted to the levels of controls (shGFP) by recombinant NRG1 treatment (Figure 7b) . Furthermore, while Notch1 inhibition was followed by p27
Kip1 accumulation, addition of NRG1 to the cells reduced the levels of p27
Kip1 to the levels observed in control cells. These data suggest that NRG1 is sufficient, at least in part, to restore the cell growth capacities that are hindered by Notch1 inhibition.
To further determine the requirement of NRG1 in Notch1-mediated melanoma cell growth, V2387 cells, that express lower endogenous levels of Notch1, were infected with a lentiviral construct expressing active Notch1 (Notch1-NIC) and subsequently with a specific shRNA against NRG1 (shNRG1-3). We found that, while forced expression of Notch1-NIC accelerated melanoma cell growth, inhibition of NRG1 expression abolished the growth promoting function of Notch1-NIC (Figure 7c) . Mechanistically, the growth inhibitory effect was associated with a decrease in phosphorylation of Akt followed by accumulation of p27 KIP1 (Figure 7d ). Taken together, these data suggest that the growth phenotype associated with Notch1 is in part dependent on NRG1 expression and the modulation of a Notch1 --NRG1 --Akt --p27
Kip1 axis. The fact that NRG1 only in part rescued cell growth following Notch1 knockdown suggests that additional Notch1-dependent functions are involved in the regulation of melanoma cell proliferation. We therefore speculated that blockade of both Notch and ERBB signaling may enhance melanoma growth inhibition. Indeed, preliminary data show that by combining a g-secretase inhibitor (GSI) with lapatinib, an EGFR/ERBB2 inhibitor, we obtain additive cell growth inhibition in a number of melanoma cells (Supplementary Figure 4) . Although preliminary and warrant of more detailed mechanistic studies, these data suggest that targeting both Notch and ERBB signaling may be a novel approach in the treatment of melanoma.
DISCUSSION
Here, we demonstrate that Notch1 and NRG1 signaling are associated in melanoma and that NRG1 constitutes a new direct Notch1 transcription target. We present evidence that NRG1 Kip1 . The growth in the presence of anti-ERBB3 antibody was repeated twice and data in (a) are the average between the two independent repeats. signaling is required for effective melanoma cell growth through the modulation of Akt and p27 Kip1 . Furthermore, we show that the NRG1 pathway is critical for the maintenance of the malignant phenotype. Finally, we show that the growth phenotype associated with Notch1 is in part attributable to the expression of NRG1 and the modulation of a Notch1 --NRG1 --Akt --p27 Kip1 axis. Together, these data provide strong indications that Notch1 lies upstream of NRG1 highlighting the existence of an autocrine signal-transducing loop involving Notch1 and NRG1 in the majority of the tumor cell lines studied herein.
Notch1 and NRG1 signaling are essential in embryogenesis and have a crucial role in the maintenance of melanoblasts and melanocyte stem cells. 15, 21, 44 Interestingly, while Notch1, NRG1 and ERBB3 were significantly associated in a number of melanoma datasets and highly expressed in most of the melanoma samples and cell lines analyzed, they were barely detectable or absent in melanocytes, suggesting that the expression of Notch1 and NRG1 signaling components might be reactivated during malignant transformation. This observation is intriguing particularly in view of other reports in which the aberrant re-expression of embryonic signaling pathways, such as Notch4 and Nodal, was shown to regulate melanoma cell plasticity and aggressiveness. 3 Our data would suggest that a similar mechanism might be in place for Notch1 and NRG1 signaling. Indeed, previous work demonstrated that inhibition of Notch1 in melanoma cells decreased their growth in vitro and in vivo. 16, 17 The data presented here highlight a new potential mechanism of Notch1-dependent melanoma growth in the identification of NRG1 as a Notch1 target. Our data show that downregulation of NRG1 in melanoma cells strongly affects their growth capacity both in vitro and in vivo and their anchorage-independent growth. Furthermore, the growth defects observed appear to be dependent on the level of NRG1 remaining in the cells. In fact, in the presence of the strongest knockdown achieved with shNRG1-5, cell growth was inhibited by 85 --90% in a number of cell lines and tumor volumes at 47 (Figure 6c ) or 53 ( Supplementary Figure 3f) days post-inoculation were still, roughly, 70 --90% smaller than control tumors (200 mm 3 vs 700 mm 3 and 100 mm 3 vs 900 mm 3 , respectively). Whether a Notch1 --NRG1 autocrine signaling loop is involved in melanoma metastasis is not known and it will be addressed in future studies. However, evidence from other tumor types would suggest that it is a likely possibility. For example, a Notch/ERBB2 cross-talk was observed in cancer stem cells of the breast and shown to contribute to cancer cell invasion and tumorigenesis. 25, 26 NRG1 signals through the engagement of ERBBB3 and ERBB4, members of the epidermal growth factor family of tyrosine kinase receptors, and promotes the activation of major survival and growth signaling cascades such as PI3Kinase and MAPKinase. 40 Although no change in Erk1/2 phosphorylation was observed, we found a strong reduction of Akt phosphorylation after NRG1 knockdown. Furthermore, we also observed the accumulation of the cell-cycle inhibitor p27
Kip1 following NRG1 knockdown that was associated with the levels of NRG1 inhibition achieved with the two shRNA sequences employed. Based on these results, we hypothesize that the effects of NRG1 on melanoma cells may be dependent on the engagement of the ERBB receptors. In fact, not only is NRG1 known to be the ligand for ERBB3 and ERBB4, both receptors have also been implicated in melanoma. Recently, ERBB3 has been found activated in both melanomas and melanoma cell lines 21, 44 and its expression levels associated with poor patient outcome; 22 ERBB4 activating mutations have been observed in up to 20% of melanomas. 23 Interestingly, when we prevented NRG1 binding to ERBB3 by using an anti-ERBB3 antibody, we observed inhibition of melanoma cell growth that was associated with the inhibition of the PI3Kinase/Akt signaling pathway and with an increase in p27 Kip1 . Taken together, these results strongly support a role for the NRG1 pathway in the modulation of melanoma growth and tumorigenic potential and suggest a potential autocrine signaling pathway. In this pathway, NRG1 exerts its growth promoting activity through signaling via the ERBB receptors, activation of the PI3Kinase/Akt signaling cascade that culminates with the suppression of the cell-cycle inhibitor p27 Kip1 . 38, 39 To further support the notion that NRG1 may be a key mediator in Notch1-dependent melanoma growth, we show that inhibition of Notch1 results in a reduction in the activity of the PI3Kinase/Akt signaling pathway and increased accumulation of p27 Kip1 . Interestingly, treatment with recombinant NRG1 partially restored the cell growth capabilities, increased Akt phosphorylation and counteracted the accumulation of p27 Kip1 . On the other hand, forced expression of active Notch1 (Notch1-NIC) accelerated cell growth but such growth promoting capabilities were ablated by the inhibition of NRG1. This behavior was associated with the deregulation of Akt and p27 KIP1 . Together, these data suggest that Notch1 promotes melanoma cell growth in part by driving the expression of NRG1, which, in turn, maintains an active PI3Kinase/ Akt signaling cascade and keeps in check the levels of the cell cycle inhibitor p27 KIP1 . The fact that NRG1 did not completely restore the cell growth capacities of cells deprived of Notch1 suggests that Notch1 may control melanoma growth via additional pathways. For example, Notch1 has been recently shown to affect lung adenocarcinoma cell survival by directly regulating the expression of IGF-1R (insulin-like growth factor 1 receptor). 46 Interestingly, an antagonistic relationship between Notch and ERBB signaling has been observed. For example, recent work 47 has demonstrated an antagonistic relationship between Notch1 and ERBB2 in breast cancer cells such that inhibition of ERBB2 activity by trastuzumab led to the activation of Notch1 signaling and resulted in acquired resistance to the drug. Dual inactivation of ERBB2 and Noch1 by trastuzumab and a GSI reversed the resistant phenotype. Similarly, Dong et al. 48 showed that only the combined inhibition of EGFR and g-secretase by gefitinib and a GSI promoted apoptosis of basal-like breast cancer cells. These results are quite in contrast with our findings where Notch and NRG1 are part of a positive autocrine signaling loop that promotes melanoma growth and suggests that the interaction between Notch and ERBB signaling could regulate different cell fates depending on the components of the ERBB pathway involved and the context of the tissue in which such interaction occurs.
Recent advances in melanoma research have led to the successful development of therapies targeted against activated BRAF (v-raf murine sarcoma viral oncogene homolog B1), thus far the most frequently mutated gene in melanoma. However, the benefits achieved with these experimental approaches are still limited to patients bearing BRAF mutations and by the emergence over time of resistant tumors. Melanomas rely on the activity of multiple signaling pathways for their growth and survival. The study presented here identifies a new mechanism of Notch1-dependent melanoma growth and provides experimental evidence that Notch1 and NRG1, two evolutionary conserved signaling cascades, are reactivated in melanoma and functionally linked. Furthermore, this work suggests that the inhibition of Notch and ERBB signaling may represent a novel potential therapeutic approach in melanoma. The therapeutic potential of this study is particularly attractive since inhibitors for both Notch signaling and the ERBB pathway already exist and are either being tested in clinical trials or are being used for the treatment of other cancers. Indeed, in preliminary studies we observed that the combination of a GSI with lapatinib, an anti-EGFR/ERBB2 compound, additively inhibits the growth of a number of melanoma cell lines (Supplementary Figure 4) . Furthermore, the treatment was equally effective on either mutated or WT (wildtype) BRAF cells. Given the fact that only about 50% of melanoma patients harbor BRAF mutations and are therefore eligible for anti-BRAF therapy, these data suggest that the use of a combined antiNotch-ERBB treatment may be beneficial to a broader cohort of melanoma patients. In conclusion, while these initial results require further validation and a more in-depth mechanistic analysis, they support the potential use of Notch and ERBB inhibitors in the treatment of melanoma.
MATERIALS AND METHODS

Cells and tissue specimens
Primary and metastatic melanoma cells were in part purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and in part were a gift from Dr Marianne Broome Powell (Stanford University) (Bedogni et al., 2008) . The use of these cells was approved by the Case Cancer Institutional Review Board (IRB). The cell lines used in this study are, in the order they appear in the blot in Figure 1g : immortalized human melanocytes; A375.52; C32TG; WM3211; V2387; WM35; WM115; UACC2521; SKMEL2; D1594; K457; UACC3291; WM266-4; SKMEL24. Functional assays were performed on the cell lines WM266-4, K457 and V2387, SKMEL2 and SKMEL24. These are human melanoma cells derived from metastases of the skin (WM266-4 and K457, SKMEL2) and lymph node (V2387, SKMEL24) and are either BRAF mutants (WM266-4, K457, V2387) or WT (SKMEL2 and 24). All cells were maintained in DMEM (Dulbecco's modied Eagle's medium) supplemented with 10% FCS (fetal calf serum), 1% glutamine and 1% penicillin --streptomycin. Immortalized human melanocytes were a gift from Dr Robert Weinberg (Harvard University) and were maintained in DMEM supplemented with 5% FCS, 1% glutamine and 1% penicillin --streptomycin. 49 De-identified melanoma tissues were redundant diagnostic specimens obtained at surgery for clinically indicated removal at metastatic sites. The collection of such specimens followed the guidelines of the IRB-approved Human Biospecimen Resource Core in the Cleveland Clinic Department of Anatomic Pathology (Institutional Review board (IRB) protocol no 06 --050).
shRNAs and expression plasmids shRNAs against human Notch1 (TRCN0000003359 and TRCN0000003362) and human NRG1 (TRCN0000058303 and TRCN0000058305) were purchased from Open Biosystems (Lafayette, CO, USA). The Notch1-NIC lentiviral expression vector was constructed by inserting the cDNA sequence corresponding to human Notch1-NIC (base pairs 5278 --7668 of full-length human Notch1) into the pLM-CMV-Ha-puro-PL3 lentiviral plasmid, 50 between XbaI --XhoI. Viral particles were produced in 293-FT (fast growing variant of the 293 cell line stably expressing SV40 large T antigen) cells using the Fugene6 reagent (Roche, Mannheim, Germany) as per the manufacturer's instructions. The packaging plasmids used were pMD2.G and psPAX2 that were purchased from Addgene (Cambridge, MA, USA).
Luciferase assays
The NRG1-reporter plasmid was constructed by inserting the À3.8 CSL core region (contained between the sequence À3984 and À3644 upstream of the NRG1 transcription stat site) fused with a minimal promoter region of the NRG1 promoter (À777 to þ 193), into the pGL3-basic luciferase plasmid. The HES1-reporter construct was a gift from R Kageyama (Kyoto University, Kyoto, Japan). WM266-4 cells (5 Â 10 4 /well, in 24-well plates) were transfected using the Fugene6 reagent (Roche) as per the manufacturer's instructions. After 36 --48 h, cells were lysed in 100 ml lysis buffer (Promega, Madison, WI, USA). A Renilla luciferase reporter plasmid driven by a CMV promoter was co-transfected with NRG1 and HES1 reporter constructs at a 1:20 ratio to assess transfection efficiency. Activities of Firefly and Renilla were assessed by the dual-luciferase Assay system (Promega) and light production was measured for 10 s in a Monolight 2010 Luminometer (Molecular Devices, Sunnyvale, CA, USA).
Western blot analysis
Cells (2 Â 10 6 cells/dish, 100-mm dishes) were plated in DMEM plus 10% FCS, allowed to adhere and then they were either collected after 24 h postseeding or serum starved for 16 h before NRG1 stimulation for 4 days. Total protein was extracted with urea lysis buffer (9 M urea; 75 mM Tris --HCl, pH 7.5 and 100 mM 2-mercaptoethanol (2-ME), and 40 --50 mg per sample were separated by 8 --10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. Nuclear proteins were extracted as follows: cells were disrupted with a Dounce homogenizer in a hypotonic buffer (20 mM HEPES, pH 7; 10 mM KCl; 1 mM MgCl 2 ; 0.1% Triton X-100; 20% glycerol; 2 mM PMSF; 5 mg/ml aprotinin; and 5 mg/ml leupeptin) and centrifuged at 850 g to obtain a pellet of nuclei. Nuclear lysates were prepared in urea buffer, and 40 --50 mg were loaded onto 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels.
Tumor samples were homogenized in RIPA buffer (50 mM Tris --Cl, pH 7.4; 150 mM NaCl; 1% NP-40; 0.25% Na-deoxycholate; 1 mM PMSF; 1 mg/ml aprotinin; 1 mg/ml leupeptin; and 1 mM Na-ortovanadate), and 50 mg were loaded on an 8% gel. Membranes were probed with the following antibodies: anti-NRG1 CRD (NeuroMab, UC Davis, Davis, CA, USA); antiphospho-Akt (Ser473), anti-phospho-Erk1/2, anti-total Akt, anti-total Erk1/2 and anti-Notch1-NIC (Cell Signaling Technologies, Beverly, MA, USA); antip27
Kip1 and anti-Notch1-TM (Santa Cruz Biotechnologies, Palo Alto, CA, USA). Bands were detected using Super Signal Detection Reagent (Thermo Scientific, Waltham, MA, USA). Loading was normalized with anti-b-actin for total lysates or LaminB1 for nuclear lysates (Santa Cruz Biotechnology).
Real-time PCR analysis cDNA was synthesized from total RNA, treated with DNaseI (Invitrogen, Grand island, NY, USA), using SuperScript first-strand synthesis system for RT --PCR (Invitrogen). In all, 1 ml cDNA was used for PCR amplification using SYBR Green PCR Master Mix (Bio-Rad, Hercules, CA, USA). The following primer sets were used to amplify specific target genes: human Notch1 forward 5 0 -GAGGCGTGGCAGACTATGC-3 0 , reverse 5 0 -CTTGTACTCCGT-CAGCGTGA-3 0 ; human NRG1 forward 5'-CAAAGAAGGCAGAGGCAAAG-3 0 , reverse 5 0 -AACTGGTTTCACACCGAAGG-3 0 ; human b-actin forward 5 0 -CATGTACGTTGCTATCCAGGC-3 0 , reverse 5 0 -CTCCTTAATGTCACGCACGAT-3 0 . PCR amplification was done in a Bio-Rad I-Cycler. b-Actin was used to normalize mRNA. Relative quantification of mRNA expression levels was determined using the relative standard curve method according to the manufacturer's instructions (Bio-Rad).
ChIP assay
ChIP was performed using ChIP assay kits (Upstate Biotechnology, Waltham, MA, USA) following the manufacturer's recommendations. The following primer sequences were used: NRG1 promoter at À3. 0 . The antibody employed for the immunoprecipitation was previously described. 51 Cell proliferation assays WM266-4 cells (2 Â 10 4 ) expressing shRNA control (shGFP) or shRNA against NRG1 (#3 and #5) were plated in triplicate in 24-well plates and were counted every 3 --4 days for the duration of the experiment using an electronic particle counter (Beckman Coulter, Indianapolis, IN, USA). For the ERBB3 antibody treatment, 3000 cells were seeded in 96-well plates in triplicate and 10 mg/ml ERBB3 antibody (Ab-5, Lab Vision-Thermo Scientific) was added in each well. Cell growth was assessed by a crystal violet assay as previously described. 52 For the treatment with recombinant NRG1 (Cell Signaling Technology), 5000 cells were seeded in 96-well plates in triplicate and treated with 5 ng/ml NRG1 for 4 days. At the end of the treatment, the cells were fixed with 10% buffered formalin and subjected to the crystal violet assay. V2387 cells expressing an empty vector (pLM) or active Notch1 (NIC) in conjunction with shGFP and shNRG1-3 were seeded in a 96-well plate (3000 cells/well) in triplicate, fixed with formalin at the time points shown and subjected to the crystal violet assay. Treatment with the g-secretase compounds RO4929097 (10 mM) and DBZ (10 mM) (dibenzazepine) and the EGFR/ERBB2 inhibitor lapatinib (20 mM) were done on WM266-4 (4000/well), K457 (2000/well) and SKMEL2 (4000/well) cells seeded in a 96-well plate. The drugs were added the following day, either alone or in combination, and 4 days later cell growth was assessed by the crystal violet assay.
Anchorage-independent growth Cells (10 5 cells/well, 24-well plates) were suspended in DMEM þ 10% FBS containing 0.3% agar and spread onto a 0.6% agar layer. Photographs were taken after 4 weeks of incubation in agar.
